Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19355121 | OLIGONUCLEOTIDES FOR PRNP MODULATION | Non-Final OA | THE BROAD INSTITUTE, INC. |
| 17711793 | SYSTEMS AND METHODS FOR PERFORMING AND MEASURING HOMOLOGOUS CHROMOSOME TEMPLATE REPAIR | Non-Final OA | The Regents of the University of California |
| 17621669 | CRISPR-CAS3 FOR MAKING GENOMIC DELETIONS AND INDUCING RECOMBINATION | Final Rejection | The Regents of the University of California |
| 17905499 | METHOD FOR THE PRODUCTION OF CONSTITUTIVE BACTERIAL PROMOTERS CONFERRING LOW TO MEDIUM EXPRESSION | Non-Final OA | BASF SE |
| 17577942 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17998486 | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS | Non-Final OA | Akouos, Inc. |
| 18014315 | CIRCULAR miRNA SPONGES | Non-Final OA | National University of Singapore |
| 17912553 | Molecular Systems and Therapies Using the Same | Final Rejection | NATIONAL UNIVERSITY OF SINGAPORE |
| 17999297 | GENETIC PHYSICAL UNCLONABLE FUNCTIONS AND METHODS OF USE THEREOF | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18134167 | OLIGONUCLEOTIDES FOR ATN1 MODULATION | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17534002 | NEUTRALIZING VACCINES AGAINST HUMAN CORONAVIRUS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17617878 | SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 17767340 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | Final Rejection | The Children's Medical Center Corporation |
| 17522594 | COMPOUNDS AND METHODS FOR REDUCING SNCA EXPRESSION | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 17840369 | METHODS FOR GENOMIC INTEGRATION | Final Rejection | AMYRIS, INC. |
| 17353440 | NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS | Final Rejection | CSL BEHRING LLC |
| 17639113 | Minimal Messenger RNAs and uses thereof | Non-Final OA | Universität Zürich |
| 17792121 | MODIFICATION OF BLOOD TYPE ANTIGENS | Final Rejection | Sana Biotechnology, Inc. |
| 17916270 | COMPOSITIONS COMPRISING A CAS12I2 VARIANT POLYPEPTIDE AND USES THEREOF | Final Rejection | Arbor Biotechnologies, Inc. |
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | Non-Final OA | Spacecraft Seven, LLC |
| 18316529 | COMPOSITIONS AND METHODS FOR INHIBITING MAPT EXPRESSION | Non-Final OA | Dicerna Pharmaceuticals, Inc. |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18180009 | BASE EDITING ENZYMES | Non-Final OA | Metagenomi Therapeutics, Inc. |
| 18053232 | ENZYMES WITH RUVC DOMAINS | Final Rejection | Metagenomi Therapeutics, Inc. |
| 17673226 | COMPOSITIONS AND METHODS FOR MODULATING SPLICING AND PROTEIN EXPRESSION | Final Rejection | Stoke Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy